Although lactogenic hormones regulate β-cell mass during pregnancy, they cannot alone explain all of the maternal changes in β-cell mass[@R2],[@R5]--[@R8]. Despite persistent elevations of placental lactogen and prolactin through the end of pregnancy and the end of lactation, respectively, β-cell proliferation peaks at midgestation in rodents and drops to the normal non-pregnant rate or below by parturition, prompting rapid normalization of β-cell mass postpartum[@R2],[@R9],[@R10] ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Therefore, to identify other genes potentially involved in regulating maternal β-cell mass, we compared the global gene expression patterns in islets from non-pregnant and pregnant (G13 15) female mice by high-throughput sequencing of cDNA ([Supplementary Table S1](#SD2){ref-type="supplementary-material"} and [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}.) and by hybridization to oligonucleotide microarrays ([Supplementary Tables S2](#SD2){ref-type="supplementary-material"}).

Among the genes most significantly induced during pregnancy were *Tph1* and *Tph2*, which encode the two isoforms of tryptophan hydroxylase, the rate-limiting enzyme in the synthesis of serotonin (5-hydroxytryptamine, 5-HT). We have shown that β-cells share with serotonergic neurons a common gene expression program and the ability to synthesize, store and secrete serotonin (Y. Ohta and M. S. G., unpublished observations). Indeed, several other serotonergic transcripts were significantly increased in islets from pregnant mice, including those encoding aromatic L-amino acid decarboxylase, the enzyme that catalyzes the second and final step in serotonin synthesis, and vesicular monoamine transporter VMAT1 ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}).

Real-time RT-PCR for *Tph1* and *Tph2* confirmed the genomic analyses ([Fig. 1a](#F1){ref-type="fig"}). Expression of *Tph1* and *Tph2* increased from the non-pregnant baseline by gestational day 6 (G6) and peaked at G12 with 527- and 7-fold increases respectively, while levels in gut, heart and brain did not change ([Supplementary Fig. S3](#SD1){ref-type="supplementary-material"}). *Tph1* expression remained high postpartum until the end of lactation, followed by a return to pre-pregnancy levels. Specific antiserum against Tph1 demonstrated the induction of Tph1 protein in pregnant mouse islets by western blot[@R11] ([Fig. 1b](#F1){ref-type="fig"}). High performance liquid chromatography (HPLC) detected low tissue levels of 5-HT in islets of non-pregnant mice, which increased 420-fold in islets from pregnant animals, but did not change in gut ([Fig. 1c, d](#F1){ref-type="fig"}).

RT-PCR amplified both *Tph1* and *Tph2* mRNA from β-cells purified from mice expressing eGFP in β-cells (MIP-GFP mice[@R12]) ([Fig. 1e](#F1){ref-type="fig"}). Immunohistochemical staining detected 5-HT and TPH1 co-localized with insulin in islets from pregnant mice ([Fig. 1f](#F1){ref-type="fig"}) and pregnant and post partum humans ([Fig. 1g, h](#F1){ref-type="fig"}; [Supplementary Fig. S3d](#SD1){ref-type="supplementary-material"}). In a test of the ability of β-cells to secrete this stored 5-HT, glucose stimulation induced secretion of insulin and 5-HT from islets isolated from pregnant mice ([Fig. 1i, j](#F1){ref-type="fig"}).

Taken together, these data demonstrate that β-cells dramatically increase synthesis, storage and secretion of 5-HT during pregnancy. This increase may modestly boost circulating 5HT levels ([Supplementary Fig. S4](#SD1){ref-type="supplementary-material"}), but likely increases local islet levels of 5-HT much more. Therefore, we tested whether 5-HT affects β-cell function and glucose metabolism during pregnancy. Because tryptophan is an essential amino acid and the K~m~ of Tph for tryptophan is higher than tissue tryptophan concentrations, dietary restriction of tryptophan can sharply drop 5-HT levels[@R13]. We found that mice fed a tryptophan-free diet from G6 to G12 and tested at G13 ([Fig. 2a](#F2){ref-type="fig"}) developed severe glucose intolerance compared to mice fed either a normal or histidine-free diet ([Fig. 2b](#F2){ref-type="fig"}). Furthermore, a less restricted diet, with 20% of normal tryptophan content, or treatment with the Tph inhibitor 4-chloro-DL-phenylalanine methyl ester hydrochloride (PCPA) also induced glucose intolerance in pregnant mice ([Fig. 2c](#F2){ref-type="fig"}), but not in non-pregnant female mice ([Fig. 2d](#F2){ref-type="fig"}). These results support the conclusion that 5-HT production is necessary for the maintenance of glucose homeostasis during pregnancy.

To determine how 5-HT might regulate islet function, we assayed the expression in islets of the 14 murine 5-HT receptors (Htr) by RT-PCR[@R14]. Several were expressed at relatively high levels in mouse islets ([Fig. 2e](#F2){ref-type="fig"}), and transcripts encoding the Gα~i~-linked receptor Htr1d and the Gα~q~-linked receptor Htr2b were detected in purified β-cells ([Fig. 2f](#F2){ref-type="fig"}). In pregnant mice, *Htr2b* expression increased significantly from G6 through G15 ([Fig. 2g](#F2){ref-type="fig"}) and normalized at the end of gestation, while *Htr1d* expression increased at the end of gestation (G17) and postpartum ([Fig. 2h](#F2){ref-type="fig"}). Interestingly, increased *Htr2b* expression closely correlated with the period of increased β-cell proliferation, and increased *Htr1d* expression correlated with the cessation of β-cell proliferation and regression of β-cell mass[@R2],[@R9].

To assess the contribution of 5-HT signaling, mice were treated with Htr antagonists ([Fig. 2a](#F2){ref-type="fig"}). Nonspecific Htr antagonist Methysergide and selective Htr2b antagonist SB204741 induced glucose intolerance in pregnant mice ([Fig. 2i](#F2){ref-type="fig"}), but not in non-pregnant female mice (SB204741, [Fig. 2d](#F2){ref-type="fig"}) or when given acutely ([Supplementary Fig. S5a](#SD1){ref-type="supplementary-material"}), while selective Htr2a antagonist Ketanserin had no effect on glucose tolerance ([Fig. 2i](#F2){ref-type="fig"}). Treatment with PCPA, SB204741, or a tryptophan-free diet all reduced insulin levels in pregnant mice ([Fig. 2j](#F2){ref-type="fig"}), but insulin sensitivity was not reduced with PCPA or SB204741 ([Supplementary Fig. S5b](#SD1){ref-type="supplementary-material"}). To test genetically the requirement for Htr2b signaling during pregnancy, we assessed *Htr2b* null mice and observed glucose intolerance during pregnancy ([Fig. 3a, b](#F3){ref-type="fig"}).

Given the known role of Htr2b signaling in driving cell proliferation in other tissues[@R15]--[@R21], we tested whether 5-HT signaling contributes to increased β-cell proliferation during pregnancy. Treatment with PCPA or SB204741 as well as *Htr2b* loss reduced the normal increase in β-cell proliferation in pregnant mice at G13 as assayed by 5-bromo-2-deoxyuridine (BrdU) incorporation ([Fig. 2a](#F2){ref-type="fig"}, [3c](#F3){ref-type="fig"}), and prevented the pregnancy-induced expansion of β-cell mass ([Fig 3d](#F3){ref-type="fig"}), but did not reduce insulin secretion acutely from islets *in vitro* ([Supplementary Fig. S5c](#SD1){ref-type="supplementary-material"}). In addition, both PCPA and SB204741 attenuated the growth of the MIN6 β-cell tumor line but not of NIH-3T3 fibroblasts ([Supplementary Fig. S6a](#SD1){ref-type="supplementary-material"}). Therefore, expansion of β-cell mass during pregnancy requires both Tph1-driven 5-HT production and signaling through Htr2b.

To determine whether the requirement for Htr2b signaling resides specifically in the islets, we transplanted islets isolated from *Htr2b^+/+^* or *Htr2b*^−/−^ mice under the kidney capsule of *Htr2b^+/+^* mice ([Fig. 3e](#F3){ref-type="fig"}) and assessed β-cell proliferation in the transplanted islets during pregnancy. Although this approach removes the islets from their normal anatomic context, it avoids the use of cre-recombinase, which when expressed under the control of pancreatic promoters often recombines targeted genes in other tissues as well[@R22]. In transplanted β-cells, pregnancy induced 5-HT production regardless of the presence of *Htr2b* ([Fig. 3f](#F3){ref-type="fig"}). However, while both the host and transplanted *Htr2b^+/+^* β-cells similarly increased BrdU incorporation during pregnancy, fewer transplanted *Htr2b*^−/−^ β-cells incorporated BrdU, demonstrating a local requirement for Htr2b signaling in islets during pregnancy ([Fig. 3g, h](#F3){ref-type="fig"}).

Because pregnancy hormones prolactin and placental lactogen stimulate β-cell proliferation[@R2],[@R3],[@R5],[@R6], and prolactin induces *Tph1* expression in the mammary gland[@R23], we tested the ability of lactogenic hormones to induce *Tph1* expression in islets isolated from pregnant mice at G3. Moderate concentrations of prolactin (200 ng ml^−1^) increased *Tph1* expression 28-fold, while high concentrations of prolactin (1,000 ng ml^−1^) corresponding to midgestation lactogen levels increased *Tph1* expression by 147-fold ([Fig. 4a](#F4){ref-type="fig"}) without affecting expression of *Tph2*, *Htr1d* or *Htr2b* ([Fig. 4b--d](#F4){ref-type="fig"}). Human placental lactogen induced Tph1 expression to similar levels in G3 mouse islets, but non-pregnant islets responded less robustly ([Supplementary Fig. S6d](#SD1){ref-type="supplementary-material"}), consistent with evidence that prolactin receptor expression and signaling increase in islets early during pregnancy[@R24] ([Supplementary Table S1](#SD2){ref-type="supplementary-material"}).

Next we tested whether 5-HT can independently induce islet cells to proliferate. Treatment of mouse islets with prolactin (1,000 ng ml^−1^) or 5-HT (10 μM) induced similar increases in proliferation as measured by BrdU incorporation ([Fig. 4e](#F4){ref-type="fig"}) and Ki67 staining ([Supplementary Fig. S6e](#SD1){ref-type="supplementary-material"}). Finally, treatment of islets with 5-HT (10 μM) *in vitro* altered cyclin gene expression in a pattern similar to that seen in islets from pregnant mice ([Fig. 4f, g](#F4){ref-type="fig"}).

Taken together, these studies suggest a simple model for the regulation of β-cell mass during pregnancy ([Fig. 4h](#F4){ref-type="fig"}). During pregnancy, lactogenic signaling induces *Tph1* expression and 5-HT synthesis in islets. 5-HT in turn functions in a paracrine/autocrine fashion through Gα~q~-coupled Htr2b to stimulate β-cell proliferation. Shortly before parturition, expression of Htr2b decreases and expression of Gα~i~-coupled Htr1d increases, generating an inhibitory signal capable of reducing β-cell proliferation and β-cell mass (M. Berger and M. S. G., unpublished data), so that β-cell mass returns rapidly to pre-pregnancy levels. While this model focuses on the regulation of β-cell mass, increasing evidence suggests that β-cell mass influences insulin production capacity and thus the risk of diabetes[@R25]--[@R27]. In addition, serotonin signaling may also directly impact insulin secretion independent of its effect on β-cell mass. Finally, similar shifts in receptor expression could possibly contribute to other peripartum changes, such as the mobilization of calcium from bone[@R18] that occurs with lactation.

Modulators of this pathway, including drugs, diet and genetic inheritance, could impact the risk of gestational diabetes, and possibly the long term risk of developing type 2 diabetes. The dual roles of serotonin in regulating mood and β-cell mass provide a possible link that could explain the association of depression with both type 2 diabetes[@R28] and gestational diabetes[@R29], as well as the diabetogenic effects of some classes of psychiatric medications[@R30]. A more complete understanding of the function of this pathway may suggest improved methods for both preventing and treating diabetes.

Methods {#S1}
=======

C57BL/6J mice were housed on a 12-h light/dark cycle in climate-controlled, pathogen-free barrier facilities. The Institutional Animal Care and Use Committees at UCSF or Juntendo University approved all studies involving mice. Mating was confirmed by the presence of a vaginal plug the next morning, designated day 0 of gestation (G0). The control amino acid diet contained 0.2% tryptophan and 0.4% histidine, and the low tryptophan diet contained 0.04% tryptophan. All drugs were administered by daily intraperitoneal injection except for BrdU, which was supplied in the drinking water at 1 mg ml^−1^.

Pancreatic islets were isolated from female mice by collagenase digestion, hand-picked and pooled. Glucose and insulin tolerance and insulin secretion tests were performed on fasting non-pregnant female or pregnant (G13) mice. Glucose and 5-HT levels were measured on whole blood, and insulin on plasma. Counting of BrdU positive β-cells and morphometric analyses were performed by serially sectioning the entire pancreas followed by staining and counting every 20^th^ section. A minimum of 3,000 insulin positive cells were counted per pancreas. Human pancreatic tissue was obtained at autopsy at the UCSF Medical Center and Hirosaki University affiliated teaching hospitals. Details of tissue processing and staining, and RT-PCR assays are provided in [Supplementary Materials](#SD1){ref-type="supplementary-material"}.

All high-throughput sequencing data in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE21860 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21860>).
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###### 5-HT production in islets during pregnancy

(**a**) mRNA levels for *Tph1* and *Tph2* measured by real time RT-PCR in islet RNA at the dates of gestation (G) or postpartum (P) indicated are shown relative to the levels in islets from non-pregnant female mice. *n* = 3 6 mice per data point. (**b**) Western blots were performed with Tph1 and β-actin antisera on protein extracted from islets of non-pregnant female (NP), pregnant (G12) and postpartum day 23 (P23) female mice and MIN6 insulinoma cells. (**c**, **d**) Tissue 5-HT concentrations were assayed by HPLC in islets (**c**) and duodenum (**d**) isolated from 3 non-pregnant (NP) and 3 pregnant (G12) female mice. (**e**) The mRNA shown were amplified by RT-PCR from mouse islets, β-cells (GFP^+^), non-β islet cells (GFP^−^), brain, and the β-cell lines MIN6 and βTC3. (**f**) Immunofluorescent staining labels pancreata from non-pregnant female (Non-preg) and G12 pregnant mice with insulin and glucagon in green and 5-HT in red. (**g**) Immunoperoxidase staining labels 5-HT and TPH1 in pancreata from non-pregnant (Non-preg), pregnant (37 weeks gestation) and postpartum day 2 human autopsies. (**h**) Immunohistochemical co-staining labels insulin (red, fluorescent) and TPH1 (black, peroxidase) in pregnant human autopsy pancreas. (**i**, **j**) Secreted insulin (**i**) and 5-HT (**j**) was assayed by ELISA (**i**) and HPLC (**j**), following a 1 hour incubation of islets isolated from pregnant (G13 G15) mice in 2 mM or 20 mM glucose. *n* = 5 groups of 40 islets. All data are presented as mean ± standard error. Statistical significance *vs.* islets cultured in 2mM glucose (**i** and **j**) or *vs.* non-pregnant control (**a** and **c**) was analyzed by Student's *t* test: \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001. Scale bar indicates 20 μm.
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###### 5-HT signaling and glucose metabolism in pregnancy

(**a**) The treatment schedules for mouse experiments are shown. (**b d**) Blood glucose levels were measured after intraperotoneal injection of 2 g kg^−1^ glucose in pregnant mice (G13) fed a tryptophan-free ("Trp-free", b), histidine-free ("His-free", b) or low tryptophan ("Low Trp", c) diet or treated with PCPA (300 mg kg^−1^ day^−1^)(**c**) or non-pregnant female mice (**d**) treated as shown. *n* = 5 18 mice per treatment group. (**e**) The Htr mRNAs shown were amplified by RT-PCR from mouse islet and brain RNA. (**f**) The mRNAs shown were amplified by RT-PCR from mouse islets, β-cells (GFP^+^), non-β islet cells (GFP^−^), brain, and β-cell lines MIN6 and βTC3. (**g**, **h**) mRNA levels for *Htr2a* and *Htr2b* (g) and *Htr1b* and *Htr1d* (**h**) measured by real time RT-PCR in islet RNA harvested at the gestational dates indicated are shown relative to the levels in islets from non-pregnant female mice. *n* = 3--6 mice per data point. (**i**) Blood glucose levels were measured after intraperitoneal injection of glucose (2 g kg^−1^)in pregnant mice treated with SB204741 (1 mg kg^−1^ day^−1^), Methysergide (3 mg kg^−1^ day^−1^) or Ketanserin (1 mg^−1^ kg^−1^ day^−1^). *n* = 5 18 mice per treatment group. (**j**) Pregnant mice were treated as in Fig. 2a with tryptophan-free diet, PCPA or SB204741 and fasted for 6 hours at G13 before measuring insulin in plasma collected before and 30 minutes after intraperitoneal injection of 2 g/kg glucose. *n* = 4 7 mice per group. All data are presented as mean ± standard error. Statistical significance *vs.* untreated control (**b**, **c**, **i** and **j**) or *vs.* non-pregnant control (**g** and **h**) was analyzed by Student's *t* test: \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.
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###### Htr2b signaling and β-cell proliferation in pregnancy

(**a**, **b**) Blood glucose levels were measured after intraperitoneal injection of glucose (2 g kg^−1^) in pregnant (**a**) and non-pregnant (**b**) mice with the genotypes shown. *n* = 4 7 mice per group. (**c**, **d**) In non-pregnant and pregnant control mice, pregnant mice treated with SB204741 or PCPA, and pregnant *Htr2b*^−/−^ mice, β-cell proliferation (**c**) was quantified by counting the percent of insulin ^+^ cells labeled with BrdU, and relative β-cell mass (**d**) was calculated as the area of insulin ^+^ cells / total pancreatic area. *n* = 4 6 mice per group. (**e**) Islets isolated from *Htr2b*^+/+^ (black) or *Htr2b*^−/−^ (red) mice were transplanted into the kidney capsule of *Htr2b*^+/+^ mice. (**f**) Immunofluorescent staining for 5-HT (red) and insulin (green) was performed on donor islets with the genotypes shown transplanted under the kidney capsule in non-pregnant or G13 pregnant hosts. (**g**) Immunofluorescent staining for insulin (red) and BrdU (green) together with DNA staining with DAPI (blue) was performed on host pancreatic islets and on donor islets with the genotypes shown transplanted under the kidney capsule in non-pregnant and G13 pregnant mice. (**h**) β-Cell proliferation in transplanted islets with the genotypes shown was quantified by counting the percent of insulin ^+^ cells labeled with BrdU in non-pregnant (NP) and pregnant mice. *n* = 3 4 per group. All data are presented as mean ± standard error. Statistical significance *vs. Htr2b*^+/+^ control (**a**), *vs.* pregnant untreated *Htr2b*^+/+^ control (**c** and **d**) or *vs.* pregnant *Htr2b*^+/+^ control (**h**) was analyzed by Student's *t* test: \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001. Scale bar indicates 20 μm.
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###### 5-HT and lactogen induced β-cell proliferation

(**a d**) mRNA levels for *Tph1* (**a**), *Tph2* (**b**), *Htr1d* (**c**) and *Htr2b* (**d**) were measured by real-time RT-PCR in RNA from islets isolated from G3 pregnant mice and cultured with the concentration of mouse prolactin (PRL) indicated for 72 hours. *n* = 3 6 per group. (**e**) β-Cell proliferation was quantified by counting the percent of insulin ^+^ cells labeled with BrdU in mouse islets cultured with prolactin (1,000 ng ml^−1^, PRL), 5-HT (10 μM) or no added hormone (control) for 4 days. n = 5 10 groups of islets per data point. (**f**, **g**) Levels of cyclin mRNAs were measured by real-time RT-PCR in RNA (**f**) from islets harvested at the dates indicated and shown relative to the levels in control islets from non-pregnant female mice or (**g**) from islets cultured with 5-HT (10 μM) for the time indicated and shown relative to the levels in control islets cultured without 5-HT for 24 hours. *n* = 4 10 groups of islets per data point. (**h**) A proposed model is shown for 5-HT regulation of β-cell proliferation during pregnancy. All data are presented as mean ± standard error. Statistical significance *vs.* untreated control (**a**, **e** and **g**) or *vs.* non-pregnant control (**f**) was analyzed by Student's *t* test: \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.
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